Drug General Information |
Drug ID |
D03TVF
|
Former ID |
DNC003945
|
Drug Name |
LY-293646
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H15NO3
|
Canonical SMILES |
C1COCCN1C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
|
InChI |
1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
|
InChIKey |
KKTZALUTXUZPSN-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
PI3K delta |
Target Info |
Inhibitor |
[1]
|
mRNA of PI3K p110 beta |
Target Info |
Inhibitor |
[1]
|
DNA-dependent protein kinase catalytic subunit |
Target Info |
Inhibitor |
[2]
|
Serine/threonine-protein kinase mTOR |
Target Info |
Inhibitor |
[3]
|
Phosphoinositide 3 kinase |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of inositol phosphate compounds
|
3-phosphoinositide biosynthesisPWY-6371:Superpathway of inositol phosphate compounds
|
3-phosphoinositide biosynthesis
|
KEGG Pathway
|
Inositol phosphate metabolism
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Phosphatidylinositol signaling system
|
Sphingolipid signaling pathway
|
mTOR signaling pathway
|
PI3K-Akt signaling pathway
|
AMPK signaling pathway
|
Apoptosis
|
Adrenergic signaling in cardiomyocytes
|
VEGF signaling pathway
|
Osteoclast differentiation
|
Focal adhesion
|
Signaling pathways regulating pluripotency of stem cells
|
Platelet activation
|
Toll-like receptor signaling pathway
|
Jak-STAT signaling pathway
|
Natural killer cell mediated cytotoxicity
|
T cell receptor signaling pathway
|
B cell receptor signaling pathway
|
Fc epsilon RI signaling pathway
|
Fc gamma R-mediated phagocytosis
|
TNF signaling pathway
|
Leukocyte transendothelial migration
|
Neurotrophin signaling pathway
|
Cholinergic synapse
|
Inflammatory mediator regulation of TRP channels
|
Regulation of actin cytoskeleton
|
Insulin signaling pathway
|
Progesterone-mediated oocyte maturation
|
Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Oxytocin signaling pathway
|
Regulation of lipolysis in adipocytes
|
Type II diabetes mellitus
|
Non-alcoholic fatty liver disease (NAFLD)
|
Aldosterone-regulated sodium reabsorption
|
Carbohydrate digestion and absorption
|
Bacterial invasion of epithelial cells
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Amoebiasis
|
Hepatitis C
|
Hepatitis B
|
Measles
|
Influenza A
|
HTLV-I infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Viral carcinogenesis
|
Proteoglycans in cancer
|
Colorectal cancer
|
Renal cell carcinoma
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Chronic myeloid leukemia
|
Acute myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancerhsa00562:Inositol phosphate metabolism
|
Choline metabolism in cancerhsa03450:Non-homologous end-joining
|
Cell cyclehsa04012:ErbB signaling pathway
|
Adipocytokine signaling pathway
|
MicroRNAs in cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
FSH Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
Apoptosis signaling pathway
|
Axon guidance mediated by netrin
|
B cell activation
|
EGF receptor signaling pathway
|
Endothelin signaling pathway
|
FGF signaling pathway
|
Hypoxia response via HIF activation
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
Integrin signalling pathway
|
PDGF signaling pathway
|
T cell activation
|
VEGF signaling pathway
|
p53 pathway
|
Ras Pathway
|
p53 pathway feedback loops 2P00005:Angiogenesis
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
p53 pathway feedback loops 2
|
CCKR signaling map STP00030:Hypoxia response via HIF activation
|
Pathway Interaction Database
|
ErbB4 signaling events
|
TRAIL signaling pathway
|
Signaling events mediated by TCPTP
|
FAS (CD95) signaling pathway
|
CXCR4-mediated signaling events
|
EGF receptor (ErbB1) signaling pathway
|
Class I PI3K signaling events
|
ErbB1 downstream signaling
|
ErbB2/ErbB3 signaling events
|
PDGFR-beta signaling pathway
|
Nephrin/Neph1 signaling in the kidney podocyte
|
Internalization of ErbB1
|
CXCR3-mediated signaling eventserbb4_pathway:ErbB4 signaling events
|
LPA receptor mediated events
|
CXCR3-mediated signaling eventsdnapk_pathway:DNA-PK pathway in nonhomologous end joining
|
Coregulation of Androgen receptor activity
|
Class I PI3K signaling events mediated by Akt
|
BARD1 signaling eventsil4_2pathway:IL4-mediated signaling events
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
IL12-mediated signaling events
|
CDC42 signaling events
|
LKB1 signaling events
|
Regulation of Telomerase
|
mTOR signaling pathway
|
EGFR-dependent Endothelin signaling events
|
IL2 signaling events mediated by PI3K
|
IFN-gamma pathway
|
CXCR3-mediated signaling events
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate MetabolismPW000659:Leucine Stimulation on Insulin SignalingPW000143:Inositol Metabolism
|
Phosphatidylinositol Phosphate Metabolism
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
Reactome
|
GPVI-mediated activation cascade
|
PIP3 activates AKT signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
G beta:gamma signalling through PI3Kgamma
|
Interleukin-3, 5 and GM-CSF signaling
|
Interleukin receptor SHC signaling
|
Regulation of signaling by CBL
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-109704:PI3K Cascade
|
PI3K/AKT activation
|
Role of phospholipids in phagocytosis
|
Tie2 Signaling
|
DAP12 signaling
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
Nephrin interactions
|
VEGFA-VEGFR2 Pathway
|
Regulation of signaling by CBLR-HSA-5693571:Nonhomologous End-Joining (NHEJ)R-HSA-1257604:PIP3 activates AKT signaling
|
Macroautophagy
|
mTORC1-mediated signalling
|
HSF1-dependent transactivation
|
CD28 dependent PI3K/Akt signaling
|
VEGFR2 mediated vascular permeability
|
TP53 Regulates Metabolic Genes
|
Constitutive Signaling by AKT1 E17K in CancerR-HSA-109704:PI3K Cascade
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
PI3K events in ERBB4 signaling
|
GAB1 signalosome
|
PI3K events in ERBB2 signaling
|
Costimulation by the CD28 family
|
G alpha (q) signalling events
|
G alpha (12/13) signalling events
|
Constitutive Signaling by EGFRvIII
|
PI-3K cascade:FGFR1
|
PI-3K cascade:FGFR2
|
PI-3K cascade:FGFR3
|
PI-3K cascade:FGFR4
|
WikiPathways
|
Toll-like receptor signaling pathway
|
DNA Damage Response (only ATM dependent)
|
Interferon type I signaling pathways
|
G13 Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
Insulin Signaling
|
IL-4 Signaling Pathway
|
Focal Adhesion
|
IL-3 Signaling Pathway
|
PI Metabolism
|
Signaling by the B Cell Receptor (BCR)
|
Interleukin-2 signaling
|
PIP3 activates AKT signaling
|
Nanoparticle-mediated activation of receptor signaling
|
Signaling Pathways in Glioblastoma
|
Interleukin-3, 5 and GM-CSF signaling
|
MicroRNAs in cardiomyocyte hypertrophy
|
Regulation of toll-like receptor signaling pathway
|
AMPK SignalingWP75:Toll-like receptor signaling pathway
|
Fc epsilon receptor (FCERI) signaling
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
DAP12 interactions
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
TCR signaling
|
Signaling by PDGF
|
Signaling by Insulin receptor
|
NGF signalling via TRKA from the plasma membrane
|
Nephrin interactions
|
GPVI-mediated activation cascade
|
Cell surface interactions at the vascular wall
|
AMPK SignalingWP707:DNA Damage Response
|
Non-homologous end joining
|
FAS pathway and Stress induction of HSP regulation
|
Cytosolic sensors of pathogen-associated DNA
|
Retinoblastoma (RB) in Cancer
|
Prostate Cancer
|
Double-Strand Break Repair
|
Cell Cycle
|
miRNA Regulation of DNA Damage ResponseWP673:ErbB Signaling Pathway
|
Senescence and Autophagy in Cancer
|
EGF/EGFR Signaling Pathway
|
Wnt Signaling Pathway Netpath
|
Extracellular vesicle-mediated signaling in recipient cells
|
Cardiac Hypertrophic Response
|
Polycystic Kidney Disease Pathway
|
Alpha 6 Beta 4 signaling pathway
|
BDNF signaling pathway
|
Oncostatin M Signaling Pathway
|
TSLP Signaling Pathway
|
FSH signaling pathway
|
Leptin signaling pathway
|
TSH signaling pathway
|
RANKL/RANK Signaling Pathway
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
Integrated Breast Cancer Pathway
|
SREBP signalling
|
Costimulation by the CD28 family
|
Type II diabetes mellitus
|
TOR Signaling
|
Serotonin HTR1 Group and FOS Pathway
|
Copper homeostasis
|
Signaling of Hepatocyte Growth Factor Receptor
|
Transcriptional activation by NRF2
|
IL1 and megakaryotyces in obesity
|
Signaling by ERBB4
|
Signaling by ERBB2
|
Signaling by SCF-KIT
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
Integrated Pancreatic Cancer Pathway
|
Regulation of Microtubule Cytoskeleton
|
Signaling by FGFR
|
Signaling by EGFR
|
GPCR downstream signaling
|
Angiogenesis
|
AMPK Signaling
|
References |
REF 1 | Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13.LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. |
---|
REF 2 | J Med Chem. 2005 Dec 1;48(24):7829-46.Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. |
---|
REF 3 | J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. |